Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation. Neither IGC,
the medical associations, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Source
Smallridge RC, Ain KB, Asa SL, et al. American yroid Association guidelines for
management of patients with anaplastic thyroid cancer. yroid, a Mary Ann Liebert, Inc.
publication. 2012;22(11):1104-39.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2015 All rights reserved
ATAANA15073a
Abbreviations
ATC, anaplastic thyroid carcinoma; CD45, protein tyrosine phosphatase receptor type C;
CEA, carcinoembryonic antigen; DTC, differentiated thyroid carcinoma; FTC, follicular
thyroid carcinoma; IMRT, intensity-modulated radiation therapy; MTC, medullary
thyroid carcinoma; NED, no evidence of disease; P53, cellular tumor antigen p53 or
tumor protein p53; PAX8, paired box protein Pax 8 or paired box 8; PTC, papillary
thyroid carcinoma; RAI, radioactive iodine; RT, radiation therapy; SCC, squamous cell
carcinoma; TTF-1, thyroid transcription factor 1; IV, intravenous
American yroid Association, Inc.
6066 Leesburg Pike, Suite 550 • Falls Church, Virginia 22041
Phone: 703.998.8890 • Fax: 703.998.8893 • www.thyroid.org
Physician referral, patient resources available online in English and Spanish.
